Ovarian cancer is one of the most lethal gynecological conditions in the developed world. Current screening methods have only made marginal differences in overall survival over the past 30 years. The deficit of early-stage detection methods is a critical factor in the mortality associated with this disease. Recent evidence has shown that the fallopian tubes are a critical site in carcinogenesis of ovarian cancers. We present the first endoscopic co-registered OCT-AFI imaging of ex vivo fallopian tubes. This work aims to evaluate the potential of OCT-AFI to identify pre-cancerous lesions in the fallopian tubes. The BC Cancer Research Centre’s Optical Imaging Lab has developed a multimodal imaging system and catheter which enables both optical coherence tomography (OCT) and autofluorescence imaging (AFI). The imaging probe consists of a dual-clad fiber optical core inside a 0.9mm diameter sterile sheath. This system allows for resolutions of 20-30μm and imaging depths of up to 1.5mm. Samples are collected from patients consented through the OVCARE Gynecological Cancer Tissue Bank banking protocol. Volumetric OCT-AFI images are acquired for the entire catheterizable length of the sample at pullback speeds of 1mm/s. After imaging, histology is conducted according to the “sectioning and extensively examining the fimbriated end” protocol to serve as a gold standard. We present methods for obtaining scans of the ex vivo fallopian tubes, sample cases correlated with histology, and our preliminary results. As of January 2020, we have imaged 21 patients and 27 fallopian tubes including 6 cancerous specimens.